The health product developer has now raised more than $71m in debt and equity financing in total having received series C funding from backers including Mayo Clinic Ventures.

Tencent, Parkway Global and returning investor Lilly Asia Ventures all contributed to a series B round that boosted the cancer immunotherapy developer's total funding to $155m.

Lilly Asia Ventures and SBCVC both invested in the cancer diagnostics technology developer as part of a round that will fund research and development and strategic partnerships.

Guerbet, Caisse Centrale de Réassurances, L’Occitane and Sopra Steria were among the backers for the life sciences-focused venture firm's BioMedTech fund.

MIT's Taris, which is developing a drug delivery system for bladder diseases, has been purchased by Johnson & Johnson.

Bristol-Myers Squibb has exited Taris, which is developing a drug delivery system for bladder diseases, in a purchase by Johnson & Johnson.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novartis, Merck & Co and Eli Lilly-backed Forma Therapeutics, which is working on treatments for rare haematologic diseases and cancers, has added $100m to its coffers.

BioMedTech will work to establish approximately a dozen spinouts from European and American universities, with a particular focus on France.